Dawson James Starts Orgenesis (ORGS) at Buy

Dawson James analyst Carol Werther initiates coverage on Orgenesis (NASDAQ: ORGS) with a Buy rating and a price target of $10.00.

The analyst commented, "The Masthercell Global subsidiary is a vertically integrated profitable contract development and manufacturing organization (CDMO). This business is focused on support services, process innovation and technology innovation to assist customers from pre-clinical stages through commercialization developing cell and gene-based approaches to treat diseases. Masthercell is profitable with sales of $10M in FY17 and we estimate growing to $21M in FY18, and to $45M in FY19 as additional capacity at the Belgium plant has been completed."

For an analyst ratings summary and ratings history on Orgenesis click here. For more ratings news on Orgenesis click here.

Shares of Orgenesis closed at $4.76 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy